Live
Endpoints NewsTakeda fortifies orexin potential with more Phase 3 dataEndpoints NewsElicio’s KRAS cancer vaccine fails in Phase 2, shares plummetFierceBiotechAmid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plantEndpoints NewsGan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataFierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatmentBioWorldBiggest gainers and losers for June 8-12, 2026FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffClinical OMICsRewriting Cancer Care Through EpigeneticsBioPharma DiveMedicare drug price rule may target under-the-skin Keytruda and OpdivoFierceBiotechTraws defers midphase flu study after negative regulatory review
Endpoints News May 1, 2026

Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit

Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit

Original
Body unavailable. Use the original source.